Open access
Open access
Powered by Google Translator Translator

Oncology – Breast

20-year follow-up of a RCT | Adjuvant Goserelin and Tamoxifen in premenopausal patients with breast cancer.

26 Sep, 2022 | 12:00h | UTC

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial – Journal of Clinical Oncology

News Release: Hormonal breast cancer treatment reduces long-term risk of recurrence – Karolinska Institutet

 

Commentary on Twitter

 


M-A | Margin status and survival outcomes after breast cancer conservation surgery.

23 Sep, 2022 | 13:09h | UTC

Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis – The BMJ

Commentary from the authors: Width of excision margins after breast conserving surgery for invasive breast cancer and distant recurrence and survival – The BMJ

News Release: Experts call for adequate tumour free margins in breast cancer surgery – BMJ Newsroom

 


Cohort Study | Fertility preservation procedures appear to be safe at the time of breast cancer diagnosis.

7 Sep, 2022 | 12:31h | UTC

Relapse Rates and Disease-Specific Mortality Following Procedures for Fertility Preservation at Time of Breast Cancer Diagnosis – JAMA Oncology

News Release: Fertility preservation measures do not appear to increase the risk of breast cancer recurrence – Karolinska Institutet

Commentary: Fertility Preservation Measures Do Not Appear to Increase the Risk of Breast Cancer Recurrence – The ASCO Post

 


Cohort Study | 5-year follow-up results suggest it is safe to de-escalate radiotherapy after primary chemotherapy in cT1–2N1 breast cancer.

31 Aug, 2022 | 11:45h | UTC

De-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Treatment De-Escalation With Locoregional Radiotherapy Appears Safe in cT1-2N1 Breast Cancer – Cancer Network

 

Commentary on Twitter

 


RCT | Sacituzumab Govitecan in hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer.

29 Aug, 2022 | 12:05h | UTC

Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer – Journal of Clinical Oncology

 


Triple negative breast cancer: pitfalls and progress.

26 Aug, 2022 | 13:02h | UTC

Triple negative breast cancer: Pitfalls and progress – npj Breast Cancer

 


Consensus Recommendations | Standardizing pathologic evaluation of breast carcinoma after neoadjuvant chemotherapy.

23 Aug, 2022 | 12:52h | UTC

Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy: Recommendations From the I-SPY Pathology Working Group – Archives of Pathology & Laboratory Medicine

 


Spindle cell lesions of the breast: a diagnostic algorithm.

23 Aug, 2022 | 12:51h | UTC

Spindle Cell Lesions of the Breast: A Diagnostic Algorithm – Archives of Pathology & Laboratory Medicine

 


Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.

18 Aug, 2022 | 12:47h | UTC

Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies – ESMO Open

Commentaries:

Prompt recognition and treatment found effective for lung disease in patients who received new drug for advanced cancer – The Mount Sinai Health System

Trastuzumab deruxtecan-related ILD/pneumonitis characterized – medwire News

Related: Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review – Drugs

 


ASCO Guideline Update | Chemotherapy and targeted therapy for human epidermal growth factor receptor 2–negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor–negative.

17 Aug, 2022 | 14:17h | UTC

Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Rapid Recommendation Update – Journal of Clinical Oncology

 


RCT | Adjuvant oral ibandronate does not improve outcomes in postmenopausal women with estrogen receptor–positive breast cancer.

16 Aug, 2022 | 13:15h | UTC

Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Adjuvant Ibandronate Not Beneficial for ER+ Breast Cancer – Cancer Therapy Advisor

 

Commentary on Twitter

 


RCT | Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast.

9 Aug, 2022 | 12:46h | UTC

Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study – The Lancet (link to abstract – $ for full-text)

 


Cohort Study | Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.

9 Aug, 2022 | 12:20h | UTC

Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer – npj Breast Cancer

 

Commentary on Twitter

 


RCT | Partial breast irradiation vs. whole breast irradiation for early breast cancer.

8 Aug, 2022 | 11:36h | UTC

Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

 


M-A | Breast cancer recurrence after immediate and delayed postmastectomy breast reconstruction.

28 Jul, 2022 | 13:05h | UTC

Breast cancer recurrence after immediate and delayed postmastectomy breast reconstruction—A systematic review and meta-analysis – Cancer

 


Systematic Review | Taxane monotherapy regimens for treating recurrent epithelial ovarian cancer.

25 Jul, 2022 | 12:47h | UTC

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer – Cochrane Library

Summary: How should we give taxane as a single chemotherapy agent to women with relapsed epithelial ovarian cancer? – Cochrane Library

 


RCT | Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer.

21 Jul, 2022 | 13:25h | UTC

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT | Oral Paclitaxel plus Encequidar vs. intravenous Paclitaxel in patients with metastatic breast cancer.

21 Jul, 2022 | 12:24h | UTC

Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer – Journal of Clinical Oncology

 

Commentary on Twitter

 


RCT | Gemcitabine vs. Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer.

14 Jul, 2022 | 12:10h | UTC

A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer – Nature Communications

 

Commentary on Twitter

 


Long-term analysis of a Phase 2 RCT | Fulvestrant plus capivasertib vs. placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor-positive, HER2-negative breast cancer.

11 Jul, 2022 | 11:48h | UTC

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial – The Lancet Oncology

News Release: New phase of breast cancer drug trial provides fresh hope for patients with incurable disease – Cardiff University

Original Study: Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial – The Lancet Oncology

 


M-A | Risk factors for anthracycline-induced cardiotoxicity in breast cancer treatment.

7 Jul, 2022 | 12:17h | UTC

Risk Factors for Anthracycline-Induced Cardiotoxicity in Breast Cancer Treatment: A Meta-Analysis – Frontiers in Oncology

 


RCT: Atezolizumab with neoadjuvant anti–human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2–positive early breast cancer.

1 Jul, 2022 | 10:28h | UTC

Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial – Journal of Clinical Oncology

Commentary: Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer – OncLive

 

Commentary on Twitter

 


ASCO Guideline Update: Biomarkers for systemic therapy in metastatic breast cancer.

29 Jun, 2022 | 11:40h | UTC

Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update – Journal of Clinical Oncology

 

Commentary on Twitter

 


Systematic Review: Trastuzumab Deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies.

29 Jun, 2022 | 10:59h | UTC

Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review – Drugs

 


Cohort Study: Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer.

27 Jun, 2022 | 11:09h | UTC

Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer – JAMA Oncology (link to abstract – $ for full-text)

News Release: Study finds breast cancers with low levels of HER2 protein are not a distinct subtype of the disease – Dana-Farber Cancer Institute

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.